Production (Stage)
Ernexa Therapeutics Inc.
ERNA
$2.29
-$0.08-3.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -94.12% | 854.90% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -94.12% | 854.90% | -- | -- |
| Cost of Revenue | -- | -100.00% | -150.00% | -- | 22.00% |
| Gross Profit | -- | 102.04% | 892.75% | -- | 72.00% |
| SG&A Expenses | -67.07% | -61.87% | -16.50% | 50.42% | 20.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -53.21% | -53.34% | -22.21% | 21.74% | 9.74% |
| Operating Income | 52.83% | 53.22% | 30.34% | -20.59% | -8.86% |
| Income Before Tax | -23.35% | 6.64% | -374.94% | -22.69% | -22.77% |
| Income Tax Expenses | 100.00% | 375.00% | 250.00% | -25.00% | -20.00% |
| Earnings from Continuing Operations | -23.39% | 6.40% | -375.84% | -22.65% | -22.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.39% | 6.40% | -375.84% | -22.65% | -22.73% |
| EBIT | 52.83% | 53.22% | 30.34% | -20.59% | -8.86% |
| EBITDA | 52.82% | 53.37% | 30.76% | -20.13% | -8.56% |
| EPS Basic | 87.49% | 86.79% | -375.82% | -20.19% | -16.31% |
| Normalized Basic EPS | 87.49% | 84.49% | -2.30% | -31.94% | -17.45% |
| EPS Diluted | 87.49% | 86.79% | -375.82% | -20.19% | -16.31% |
| Normalized Diluted EPS | 87.49% | 84.49% | -2.30% | -31.94% | -17.45% |
| Average Basic Shares Outstanding | 886.34% | 608.56% | 0.00% | 2.02% | 5.52% |
| Average Diluted Shares Outstanding | 886.34% | 608.56% | 0.00% | 2.02% | 5.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | 0.18% | -- |